Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. (Q44320317)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24781014%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

title

Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24781014%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

acute myeloid leukemia

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24781014%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

María J Blanco-Prieto

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24781014%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

author name string

A Dominguez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24781014%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

D J Christensen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24781014%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

I Moreno-Miralles

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24781014%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

M P Vitek

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24781014%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

M D Odero

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24781014%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

language of work or name

1 reference

30 April 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24781014%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24781014%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24781014%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24781014%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

page(s)

1915-1918

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24781014%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2014.141

17 March 2020

exact match

0 references

cites work

Protein phosphatase 2A: a target for anticancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.141

PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.141

Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.141

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.141

Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.141

Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.141

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.141

Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.141

Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.141

Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.141

Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.141

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.141

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.141

Functional domains of template-activating factor-I as a protein phosphatase 2A inhibitor

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24781014

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.141